Over the past 60 days in the cell therapy sector, one of the most striking trends has been strategic pullbacks and restructuring by formerly committed companies, even as core innovation continues elsewhere in the biotech ecosystem. After years of heavy investment and high expectations, several major players have opted to re‑evaluate or wind down their cell therapy operations, citing competitive pressures, shifting priorities, and capital allocation decisions.
These moves have sent ripples across the industry and prompted fresh discussion about the direction of advanced therapies in the years to come. [Read more…]
